cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Nkarta Inc
8 own
3 watching
Current Price
$6.82
$-0.35
(-4.88%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
124.13M
52-Week High
52-Week High
16.24000
52-Week Low
52-Week Low
1.28000
Average Volume
Average Volume
1.53M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization124.13M
icon52-Week High16.24000
icon52-Week Low1.28000
iconAverage Volume1.53M
iconDividend Yield--
iconP/E Ratio--
What does the Nkarta Inc do?
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company s approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Read More
How much money does Nkarta Inc make?
News & Events about Nkarta Inc.
Globe Newswire
10 months ago
7 of 10 r/r NHL patients achieved complete response (70% CR rate) following treatment with NKX019 monotherapy at 1 billion and 1.5 billion CAR NK cells per dose in the Phase 1 dose escalation studyData demonstrate potential for redosing of allogeneic CD19 CAR NK to deepen response or restore ...
Globe Newswire
1 year ago
SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at two upcoming investor conferences: 22nd Annual Needham Virtual ...
Globe Newswire
1 year ago
SOUTH SAN FRANCISCO, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at three upcoming investor conferences: SVB Securities Global Biopharma ...
Ticker Report
1 year ago
Nkarta, Inc. (NASDAQ:NKTX Get Rating) has been given a consensus rating of Moderate Buy by the ten analysts that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating on ...
Globe Newswire
1 year ago
Improved Anti-Tumor Activity Demonstrated by the Combination of NKX019 and a CD20-directed Monoclonal Antibody in Preclinical Models Pulsed Stimulation of NK Cells Derived from Peripheral Blood of Healthy Donors Induces Billion-Fold Expansion, Enabling Commercial-Scale Production of NK Cell Therapy ...
Frequently Asked Questions
Frequently Asked Questions
What is Nkarta Inc share price today?
plus_minus_icon
Can Indians buy Nkarta Inc shares?
plus_minus_icon
How can I buy Nkarta Inc shares from India?
plus_minus_icon
Can Fractional shares of Nkarta Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Nkarta Inc stocks?
plus_minus_icon
What is today’s traded volume of Nkarta Inc?
plus_minus_icon
What is today’s market capitalisation of Nkarta Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Nkarta Inc?
plus_minus_icon
What percentage is Nkarta Inc down from its 52-Week High?
plus_minus_icon
What percentage is Nkarta Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$6.82
$-0.35
(-4.88%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
RELMADA THERAPEUTICS INC
RELMADA THERAPEUTICS INC
$3.70
$-0.16 (-4.15 %)
CUE BIOPHARMA INC
CUE BIOPHARMA INC
$1.41
$-0.01 (-0.70 %)
Fulcrum Therapeutics Inc
Fulcrum Therapeutics Inc
$7.13
$-0.15 (-2.06 %)
Annexon Inc
Annexon Inc
$4.59
$0.14 (3.15 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
RELMADA THERAPEUTICS INC
RELMADA THERAPEUTICS INC
$3.70
$-0.16 (-4.15 %)
CUE BIOPHARMA INC
CUE BIOPHARMA INC
$1.41
$-0.01 (-0.70 %)
Fulcrum Therapeutics Inc
Fulcrum Therapeutics Inc
$7.13
$-0.15 (-2.06 %)
Annexon Inc
Annexon Inc
$4.59
$0.14 (3.15 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00